Display options
Cite
Yuniadi Y, Kusnadi Y, Sandhow L, et al. Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure. Cardiol Res Pract. 2016;2016:3942605doi: 10.1155/2016/3942605.
Yuniadi, Y., Kusnadi, Y., Sandhow, L., Erika, R., Hanafy, D. A., Sardjono, C., Kaligis, R. W., Kasim, M., & Harimurti, G. M. (2016). Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure. Cardiology research and practice, 20163942605. https://doi.org/10.1155/2016/3942605
Yuniadi, Yoga, et al. "Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure." Cardiology research and practice vol. 2016 (2016): 3942605. doi: https://doi.org/10.1155/2016/3942605
Yuniadi Y, Kusnadi Y, Sandhow L, Erika R, Hanafy DA, Sardjono C, Kaligis RW, Kasim M, Harimurti GM. Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure. Cardiol Res Pract. 2016;2016:3942605. doi: 10.1155/2016/3942605. Epub 2016 Apr 11. PMID: 27148465; PMCID: PMC4842367.
Copy Download .nbib Format: NLM
Share it on

Cardiol Res Pract. 2016;2016:3942605. doi: 10.1155/2016/3942605. Epub 2016 Apr 11.

Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure.

Cardiology research and practice

Yoga Yuniadi, Yuyus Kusnadi, Lakshmi Sandhow, Rendra Erika, Dicky A Hanafy, Caroline Sardjono, R W M Kaligis, Manoefris Kasim, Ganesja M Harimurti

Affiliations

  1. Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia and National Cardiovascular Center Harapan Kita, Jakarta 11420, Indonesia.
  2. Stem Cell and Cancer Institute, Jakarta 13210, Indonesia.

PMID: 27148465 PMCID: PMC4842367 DOI: 10.1155/2016/3942605

Abstract

Background. Proangiogenic Hematopoietic Cells (PHC) which comprise diverse mixture of cell types are able to secrete proangiogenic factors and interesting candidate for cell therapy. The aim of this study was to seek for benefit in implantation of PHC on functional improvement in end stage coronary artery disease patients with advanced heart failure. Methods. Patients with symptomatic heart failure despite guideline directed medical therapy and LVEF less than 35% were included. Peripheral blood mononuclear cells were isolated, cultivated for 5 days, and then harvested. Flow cytometry and cell surface markers were used to characterize PHC. The PHC were delivered retrogradely via sinus coronarius. Echocardiography, myocardial perfusion, and clinical and functional data were analyzed up to 1-year observation. Results. Of 30 patients (56.4 ± 7.40 yo) preimplant NT proBNP level is 5124.5 ± 4682.50 pmol/L. Harvested cells characterized with CD133, CD34, CD45, and KDR showed 0.87 ± 0.41, 0.63 ± 0.66, 99.00 ± 2.60, and 3.22 ± 3.79%, respectively. LVEF was improved (22 ± 5.68 versus 26.8 ± 7.93, p < 0.001) during short and long term observation. Myocardial perfusion significantly improved 6 months after treatment. NYHA Class and six-minute walk test are improved during short term and long term follow-up. Conclusion. Expanded peripheral blood PHC implantation using retrograde delivery approach improved LV systolic function, myocardial perfusion, and functional capacity.

References

  1. Mayo Clin Proc. 2009 Oct;84(10):876-92 - PubMed
  2. Circulation. 2000 Sep 5;102(10):1126-31 - PubMed
  3. Eur J Heart Fail. 2010 Jul;12(7):721-9 - PubMed
  4. Heart. 2000 May;83(5):505-10 - PubMed
  5. Am J Cardiol. 1990 Oct 16;66(13):55E-62E - PubMed
  6. Circ Res. 2003 May 16;92(9):1049-55 - PubMed
  7. J Leukoc Biol. 2013 May;93(5):639-41 - PubMed
  8. Biomed Res Int. 2013;2013:547902 - PubMed
  9. Circulation. 2002 Jan 29;105(4):539-42 - PubMed
  10. Ann Clin Lab Sci. 1971 Sep-Oct;1(2):131-3 - PubMed
  11. Cardiovasc Revasc Med. 2005 Jul-Sep;6(3):99-107 - PubMed
  12. Circulation. 2004 Nov 9;110(19):3136-42 - PubMed
  13. Am Heart J. 2011 Jun;161(6):1078-87.e3 - PubMed
  14. Circulation. 2003 Mar 4;107(8):1164-9 - PubMed
  15. Exp Cell Res. 1970 Aug;61(2):387-96 - PubMed
  16. Eur Heart J. 2001 Aug;22(15):1318-27 - PubMed
  17. J Am Coll Cardiol. 2013 Jun 11;61(23):2329-38 - PubMed
  18. Stem Cells Int. 2011;2011:310928 - PubMed
  19. JAMA. 2004 Jul 21;292(3):344-50 - PubMed
  20. Circ Res. 2013 Aug 30;113(6):646-59 - PubMed
  21. Circ Res. 2015 Apr 10;116(8):1361-77 - PubMed
  22. J Mol Cell Cardiol. 2006 Jan;40(1):24-34 - PubMed
  23. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):288-93 - PubMed
  24. Am Heart J. 1991 Apr;121(4 Pt 1):1244-63 - PubMed
  25. Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):91-4 - PubMed
  26. Cytometry A. 2015 Jan;87(1):5-19 - PubMed
  27. N Engl J Med. 2002 Oct 31;347(18):1397-402 - PubMed
  28. Sheng Li Xue Bao. 2004 Jun 25;56(3):357-64 - PubMed

Publication Types